Myriad Genetics Inc (MYGN)

MYGN (NASDAQ:Diversified Services) EQUITY
pos +0.00
Today's Range: 38.84 - 39.81 | MYGN Avg Daily Volume: 809,300
Last Update: 10/09/15 - 4:00 PM EDT
Volume: 0
YTD Performance: 15.06%
Open: $0.00
Previous Close: $39.38
52 Week Range: $30.30 - $41.81
Oustanding Shares: 68,604,579
Market Cap: 2,701,648,321
6-Month Chart
TheStreet Ratings Grade for MYGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 5 4 3
Moderate Buy 0 0 0 0
Hold 6 6 7 8
Moderate Sell 0 0 0 0
Strong Sell 2 2 2 2
Mean Rec. 2.48 2.48 2.64 2.79
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 36.46
Price Earnings Comparisons:
MYGN Sector Avg. S&P 500
36.46 36.60 25.42
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
16.99% 2.43% 45.04%
Revenue -7.10 0.46 0.13
Net Income -54.50 -0.28 -0.10
EPS -52.20 -0.16 -0.06
Earnings for MYGN:
Revenue 0.72B
Average Earnings Estimates
Qtr (09/15) Qtr (12/15) FY (06/16) FY (06/17)
Average Estimate $0.35 $0.42 $1.64 $1.82
Number of Analysts 10 8 12 10
High Estimate $0.36 $0.46 $1.73 $2.15
Low Estimate $0.33 $0.39 $1.52 $1.25
Prior Year $0.25 $0.40 $1.45 $1.64
Growth Rate (Year over Year) 39.60% 4.69% 13.22% 10.68%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
The stock still maintains a bullish slant on the daily chart.
Aug 25, 2015 | 7:11 AM EDT
MYGN was upgraded from Market Perform to Outperform, Wells Fargo said. Recent meeting with management confirms a better business outloo...
Feb 04, 2015 | 7:51 AM EST
MYGN was downgraded from Neutral to Underperform, Credit Suisse said. $30 price target. Estimates also cut, given the company's new gui...
Feb 04, 2015 | 7:40 AM EST
MYGN was upgraded from Market Perform to Outperform, JMP Securities said. $50 price target. Stock is attractive, following a 15% declin...
Charting setups in Myriad Genetics, Clovis Oncology and Aegerion Pharma.
Apr 02, 2014 | 8:16 AM EDT
MYGN raised its number, Jefferies said. Driven by unexpected boost to BRCA pricing. $33 price target. 
Feb 07, 2014 | 8:25 AM EST
MYGN was upgraded from Underperform to Neutral, Credit Suisse said. $29 price target. Base business can hold up better than expected an...
Feb 05, 2014 | 7:58 AM EST
MYGN was upgraded from Underperform to Market Perform, JMP Securities said. Company is executing well, despite increased competition.&n...
Dec 30, 2013 | 7:41 AM EST
MYGN was downgraded from Market Perform to Underperform, JMP Securities said. $15 price target. BRCA pricing is lower than expected.&nb...
Dec 03, 2013 | 8:16 AM EST
MYGN was downgraded from Outperform to Market Perform, JMP Securities said. Company could face lower reimbursement levels.

Columnist Conversations
I'm in a buy mode at the moment, but think it's a good idea to ratchet up stops on longs in Crude...the video ...
Have a great weekend as well. DXD chart for viewing pleasure. DXD working on ninth straight negative close, ...
As we might expect, the big decline in Oil prices triggered a mirror-image reverse trend in the CAD vs. USD, w...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.